Novelty or Prudence? The Delicate Balance in Pharmacological Updates
October 2025
in “
Actualización en Medicina de Familia
”
TLDR New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
The document discusses four newly commercialized pharmacological innovations: bempedoic acid (and bempedoic acid/ezetimibe) and icosapent ethyl for cardiovascular prevention, both facing challenges in therapeutic positioning due to limited evidence. Vibegron is highlighted for overactive bladder treatment, and abaloparatide for postmenopausal osteoporosis, though it shows no advantage over teriparatide. Safety updates include recommendations to minimize suicidal risks with finasteride, an infrequent ocular reaction from semaglutide, and the risk-benefit balance of metamizole. Additionally, the Prescrire update for 2025 drugs is reviewed.
